无创诊断肝硬化门静脉高压症:血清标志物还是影像学检查？

doi:10.3969/j.issn.1672-5069.2022.01.003

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (1): 9-12.doi: 10.3969/j.issn.1672-5069.2022.01.003

无创诊断肝硬化门静脉高压症:血清标志物还是影像学检查？

陈靖, 朱月永

350005 福州市福建医科大学附属第一医院肝病中心/肝病研究所

收稿日期:2021-10-07 发布日期:2022-01-12
通讯作者: 朱月永,E-mail:ezhu066@sina.com
作者简介:陈靖,男,46岁,主任医师,副教授,硕士生导师。主要从事门静脉高压的诊治研究。E-mail:mykelchen@sina.com

Non-invasive diagnosis of portal hypertension in patients with liver cirrhosis: serum markers or imaging?

Chen Jing, Zhu Yueyong

Liver Research Center, Institute for Liver Diseases, First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China

Received:2021-10-07 Published:2022-01-12

摘要/Abstract

关键词: 肝硬化, 门静脉高压症, 肝静脉压力梯度, 无创诊断

Key words: Liver cirrhosis, Portal hypertension, Hepatic venous pressure gradient, Non-invasive diagnosis

陈靖, 朱月永. 无创诊断肝硬化门静脉高压症:血清标志物还是影像学检查？[J]. 实用肝脏病杂志, 2022, 25(1): 9-12.

Chen Jing, Zhu Yueyong. Non-invasive diagnosis of portal hypertension in patients with liver cirrhosis: serum markers or imaging?[J]. Journal of Practical Hepatology, 2022, 25(1): 9-12.

[1] Simbrunner B,Marculescu R,Scheiner B,et al.Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different etiologies of advanced chronic liver disease.Liver Int,2020,40(7):1713-1724.
[2] Sandahl TD,McGrail R,Moller HJ,et al.The macrophage activation marker sCD163 combined with markers of the enhanced liver fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis. Aliment Pharmacol Ther,2016,43(11):1222-1231.
[3] Wang L,Feng Y,Ma X,et al.Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis.Plos One,2017,12(8):e0182969.
[4] Ferlitsch M,Reiberger T,Hoke M,et al.von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.Hepatology,2012,56(4):1439-1447.
[5] Maieron A,Salzl P,Peck-Radosavljevic M,et al.von Willebrand factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C.Aliment Pharmacol Therapeut,2014,39(3):331-338.
[6] Hametner S,Ferlitsch A,Ferlitsch M, et al.The VITRO score (von Willebrand factor antigen/thrombocyte ratio) as a new marker for clinically significant portal hypertension in comparison to other non-invasive parameters of fibrosis including ELF test.Plos One,2016,11(2):e0149230.
[7] Langholm LL,Manon-Jensen T,Karsdal MA,et al.Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis.Eur J Gastroenterol Hepatol,2019,31(8):1040-1048.
[8] Kim MY,Suk KT,Baik SK,et al.Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis.Hepatology,2012,56(3):1053-1062.
[9] Shimada T,Maruyama H,Kondo T,et al.Impact of splenic circulation:non-invasive microbubble-based assessment of portal hemodynamics.Eur Radiol,2015,25(3):812-820.
[10] Gupta I,Eisenbrey JR,Machado P,et al.Diagnosing portal hypertension with noninvasive subharmonic pressure estimates from a US contrast agent.Radiology,2021,298(1):104-111.
[11] Maruyama H,Yokosuka O.Ultrasonography for noninvasive assessment of portal hypertension.Gut Liver,2017,11(4):464-473.
[12] Thiele M,Hugger MB,Kim Y,et al.2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis:An individual patient data meta-analysis.Liver Int,2020,40(6):1435-1446.
[13] Hu X,Huang X,Hou J,et al.Diagnostic accuracy of spleen stiffness to evaluate portal hypertension and esophageal varices in chronic liver disease:a systematic review and meta-analysis.Eur Radiol,2021,31(4):2392-2404.
[14] Sartoris R,Rautou PE,Elkrief L,et al.Quantification of liver surface nodularity at CT:utility for detection of portal hypertension.Radiology,2018,289(3):698-707.
[15] Sartoris R,Lazareth M,Nivolli A,et al.CT-based liver surface nodularity for the detection of clinically significant portal hypertension: defining measurement quality criteria.Abdom Radiol (NY),2020,45(9):2755-2763.
[16] Bane O,Peti S,Wagner M,et al.Hemodynamic measurements with an abdominal 4D flow MRI sequence with spiral sampling and compressed sensing in patients with chronic liver disease.J Magnet Reson Imaging,2019,49(4):994-1005.
[17] Mesropyan N,Isaak A,Faron A,et al.Magnetic resonance parametric mapping of the spleen for non-invasive assessment of portal hypertension.Eur Radiol,2021,31(1):85-93.
[18] Hectors SJ,Bane O,Kennedy P,et al.Noninvasive diagnosis of portal hypertension using gadoxetate DCE-MRI of the liver and spleen.Eur Radiol,2021,31(7):4804-4812.
[19] Ronot M,Lambert S,Elkrief L,et al.Assessment of portal hypertension and high-risk oesophageal varices with liver and spleen three-dimensional multifrequency MR elastography in liver cirrhosis.Eur Radiol,2014,24(6):1394-1402.
[20] Wagner M,Hectors S,Bane O,et al.Noninvasive prediction of portal pressure with MR elastography and DCE-MRI of the liver and spleen:Preliminary results.J Magnet Reson Imaging,2018,48(4):1091-1103.

无创诊断肝硬化门静脉高压症:血清标志物还是影像学检查？

Non-invasive diagnosis of portal hypertension in patients with liver cirrhosis: serum markers or imaging?

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郑小勤, 徐辉, 李丽, 靳华, 汪晓军, 勾春燕. 家族聚集性原发性胆汁性肝硬化患者临床特征分析[J]. 实用肝脏病杂志, 2022, 25(2): 207-210.
[2]	曾议, 李国, 李红翠, 彭雅松, 田峰, 王小军. 熊去氧胆酸治疗原发性胆汁性胆管炎患者疗效及对血清Nrf2和HO-1水平的影响[J]. 实用肝脏病杂志, 2022, 25(2): 211-214.
[3]	郝玉婷, 林洁, 秦杰. 长期接受恩替卡韦治疗的乙型肝炎肝硬化患者血清水通道蛋白8和水通道蛋白9变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(2): 243-246.
[4]	王本贤, 李伟, 李东生, 李华. 腹水浓缩回输联合抗感染治疗失代偿期乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 247-250.
[5]	余涛, 付路路, 陈方, 田园. 超声造影灌注时相分析在肝硬化背景下对肝脏增生结节的诊断价值[J]. 实用肝脏病杂志, 2022, 25(2): 267-270.
[6]	何福亮, 马琳, 李悦榕, 王宇, 王民, 冯丽娟, 张冠华, 欧晓娟, 刘福全, 贾继东. 非肝硬化性门脉高压的临床诊断[J]. 实用肝脏病杂志, 2022, 25(1): 1-4.
[7]	张裕, 刘福全. 经颈静脉门体静脉分流术精准技术与合理分流道的建立^*[J]. 实用肝脏病杂志, 2022, 25(1): 5-8.
[8]	徐艳, 于秉楠, 武剑. 自身免疫性肝炎和原发性胆汁性肝硬化患者自身免疫性甲状腺疾病流行率调查^*[J]. 实用肝脏病杂志, 2022, 25(1): 42-45.
[9]	周晓永, 白阳秋, 杨惠, 张炳勇, 曲波. 原发性胆汁性胆管炎患者血清甲状腺激素水平和抗甲状腺抗体阳性率变化^*[J]. 实用肝脏病杂志, 2022, 25(1): 46-49.
[10]	李艳乐, 刘笑宇, 姚建宁, 王春峰, 张连峰, 张学秀. 乙型肝炎肝硬化并发肝性脑病患者血氨水平与认知障碍关系研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 74-78.
[11]	王菁, 毕宁, 方亮, 田园. 乙型肝炎肝硬化并发自发性细菌性腹膜炎患者CD64指数及血清sTREM-1和IL-6水平变化与肠黏膜屏障功能关系研究[J]. 实用肝脏病杂志, 2022, 25(1): 79-82.
[12]	吴玲, 李锋. 非选择性beta受体阻滞剂治疗肝硬化门脉高压症患者研究进展^*[J]. 实用肝脏病杂志, 2022, 25(1): 144-147.
[13]	吴晓枫, 黄怡, 杨如杏, 邓少东, 张静莹, 官成浓, 王颖. 原发性胆汁性肝硬化患者外周血丝氨酸蛋白酶抑制剂A1基因多态性分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 855-858.
[14]	石翠翠, 刘彦君, 章瑞南, 李光明, 范建高. 肝硬化患者血脂异常分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 859-862.
[15]	柳梅, 时永红, 郇娟, 陈茂丽. 失代偿期肝硬化患者并发医院内感染病原菌类别及其耐药特点分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 863-866.